NIA's Director of Regulatory Affairs, Dr Blanca Suarez Merino, will be presenting at the Nano2Clinic meeting in Zagreb on March 3rd. Her presentation, 'Regulatory aspects of clinical translation of nano-enabled products', will focus on regulatory barriers and challenges hampering the potential of nanomedicine in clinical practice and will look into current activities envisaged to bridge the gap between lab research and industrial manufacturing.
The aims of the Nano2Clinic meeting are to strengthen relations between industry, R&D&I sector, regulatory agencies, clinics, and patients with the ultimate goal of fostering the clinical translation of nanomedicine from bench to bedside. By promoting scientific exchanges, technological implementation and innovative solutions, the meeting will enable dialogue for rationalizing and focusing research efforts at the EU level in dealing with the challenge of nanomedicine translation for cancer therapies.
